BSD Medical Corporation (BSDM)’s Investor and Analyst Conference Call Transcript

In the third phase really is to get going and we’re simultaneously be in these phases right now and I’ll be looking forward to sharing from the building blocks of that with you.

Turning to page 4, the sixty day assessment. The good news for share holders is I did a significant amount of diligence looking at the company from the outside and had fortunately a background in med tech as of the last twenty years. They gave me resources to look at this and find out this is something in this company before, I dive into it and get a word for the share holders. And the good news is that, we have wonderful products. Hyperthermea has done amazing things over the decade for cancer patients, for physicians for hospitals to treat this terrible disease. Microwave ablation is the best in class in the growing category. We’ll share those numbers with you in a few minutes. And at its core BSD medical has really been one of the pioneers in cancer tumor ablation.

So, we have great, great products. What we have had is a strategy that clearly requires the change in direction, when you look at the stock evaluation. And when you look at the financial performance of the company. And if I step back pragmatic about which technology, I think is better. We clearly just need to focus on just one technology. So the board, in conjunction with management has decided to focus on microwave ablation and so, exit the business of Hyperthermea. Many of you have been share holders, some for a long time and I know there’s a lot of passion. Around the capabilities clinically of Hyperthermia. I share that passion and we want to ensure that Hyperthermea, finally takes place and is able to continue on in a effective manner for patients and for doctors.